

ASX ANNOUNCEMENT

20th February 2023

MICHIGAN CHILDREN'S HOSPITAL SUCCESSFULLY COMPLETES INTERNAL SYSTEMS PILOT PROGRAM AND COMMENCES FIRST ASTHMA PATIENTS ON WHEEZO REMOTE PATIENT MONITORING (RPM) PROGRAM OFFERED TO ALL ELIGIBLE PATIENTS

Highlights:

- Michigan Children's Hospital (Detroit Medical Center, DMC) commences patients on wheezo® RPM program.
- wheezo® RPM program offered to all eligible children with asthma (not as a pilot program).
- Respire to provide onsite clinical staff to manage and expedite patient onboarding.

Respire Limited (ASX:RSH) ("Respire" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce that Michigan Children's Hospital, a department within the large Detroit Medical Center and part of Tenet Health (NYSE:THC), has successfully completed the internal systems pilot program assessment and pulmonologists have commenced prescribing the wheezo® RPM program to children suffering with asthma.

Effective immediately, Michigan will now move to include wheezo® RPM program as an important addition to the standard of care for eligible children with asthma. The wheezo® RPM program will not be limited by patient number caps but offered to all eligible children requiring RPM clinical support. The program will see Respire's RPM partner Access Telehealth provide the full RPM solution, including patient and parent/carer engagement, to be reimbursed to the Michigan Children's Hospital through Centers of Medicare & Medicaid Services (CMS) and other private insurers. RPM service reimbursement is mandated in the state of Michigan requiring all payors to reimburse such services provided.

wheezo® RPM is now prescribed by pulmonologists at Michigan Children's Hospital to eligible children suffering from asthma and under their supervision, Access Telehealth will provide patient and parent/carer engagement and physician exception feedback services, all proven to improve patient compliance and health outcomes leading to reduced re-admissions and asthma attacks.

Given the potential size of the eligible patient pool, Respire will fund and provide an on-site clinical staff member to work with physicians and hospital staff to help expedite patient onboarding. Discussions relating to broadening the wheezo® RPM program reach across the larger group have commenced.

Over the past few months Michigan Children's Hospital, Access Telehealth and Respire have been assessing the wheezo® RPM program roll out to ensure that it is integrated within hospital systems and processes. Further, reimbursement of the program together with cost reductions resulting from reduced patient re-admissions makes this an economically viable hospital service.

Michigan Children's Hospital, an affiliate of Detroit Medical Center (DMC), is one of the largest children's hospitals in the USA and provides extensive asthma outpatient services. The Michigan Children's Hospital is a premier healthcare service provider for the reported 70,000 children living with asthma in the city of Detroit and recognised as a respiratory management leader.

CEO and Managing Director of Respiro, Mr Marjan Mikel said “The due diligence afforded to the wheezo® RPM program by the Michigan Children’s Hospital team has required significant time investment however we are very excited about how the program can positively impact the lives of children. In another first for Respiro, we will have onsite staff to help expedite the patient onboarding process, another example of our close partnership with Michigan Children’s Hospital. Having this program now available to all eligible children with asthma will have a material impact on their lives.”

Respiro continues to build its US business footprint with key opinion leaders, like Michigan Children’s Hospital, recognising the importance of including wheezo® RPM as part of the total management solution for respiratory patients.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiro Limited
P: +61 408 462 873
E: marjan@respiro.co

Mr Nicholas Smedley
Executive Chairman
Respiro Limited
P: +61 447 074 160
E: nicholas@respiro.co

This ASX announcement has been authorised for release by the Board of Directors of Respiro Limited.

About Respiro Limited

Respiro is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiro's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiro’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiro Limited's operations are based in Melbourne, Australia.

For additional information about Respiro and its products, please visit www.respiro.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiro Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiro current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiro only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.